OnKure

OnKure Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of precision medicines for cancer. The company targets cancers with PI3Kα mutations, which are among the most common oncogenic mutations.

OnKure's business model revolves around the discovery and development of targeted oncology therapeutics. The company aims to create "best-in-class" treatments that are highly selective for mutations, which could lead to better efficacy and fewer side effects for patients. The company is publicly traded on Nasdaq (OKUR) and recently completed a merger with Reneo Pharmaceuticals, along with a $65 million private placement, to fund its clinical trials and research and development activities. Its lead product candidate, OKI-219, is currently in a Phase 1b/2 clinical trial (PIKture-01) for the treatment of various solid tumors with PI3Kα mutations.

Keywords: biopharmaceutical, precision medicine, oncology, PI3Kα mutations, clinical-stage, targeted therapy, cancer treatment, drug development, solid tumors, oncogenic mutations